TABLE 1

Characteristics of All Patients Investigated in This Study

Patient no.	Age (y)	⁶⁸Ga-PSMA-617 (MBq)	Gleason score	PSA (ng/mL)	Previous treatment	LN metastases	Bone metastases	Local relapse	Soft-tissue metastases	Primary tumor
1^*	66	237	7	0.40	RPx + RT	0	0	0	0	0
2	55	295	8	6.40	RPx	>10	0	0	0	0
3	73	286	7	10.30	RPx	8	0	0	0	0
4^*	49	255	7	0.10	RPx + RT	0	0	0	0	0
5	69	262	5	1.30	RPx + RT	0	0	1	0	0
6	71	178	7	4.90	RPx	3	0	0	0	0
7^*	71	68	7	1.30	RPx + RT	0	0	0	0	0
8	47	138	6	2.81	RPx	2	0	0	0	0
9^*	64	238	8	0.40	RPx	0	0	0	0	0
10	60	194	7	2.90	RPx + RT + ADT	0	0	1	0	0
11	69	177	8	5.16	RPx + RT + ADT	0	1	0	0	0
12	60	151	6	24.30	Biopsy	0	0	0	0	1
13^*	70	149	7	0.22	RPx	0	0	0	0	0
14	75	164	7	1.40	RPx	0	0	1	0	0
15	59	132	7	1.30	RPx + RT + ADT	1	0	0	0	0
Dosimetry
16	67	260	7	6.60	RPx + RT	2	0	0	0	0
17	75	230	9	14.91	RPx + ADT	>10	0	0	0	0
18	61	213	NA	13.70	ADT	0	0	0	0	2
19	60	221	NA	2.86	RT	>10	>10	0	0	0

↵* Patients without pathologic tracer uptake in ⁶⁸Ga-PSMA-617 PET/CT (n = 5).
RPx = radical prostatectomy; RT = radiation therapy; ADT = androgen-deprivation therapy; NA = not available.